Comparative study of sparfloxacin and ofloxacin in chronic respiratory tract infections by the double blind method

Rinzo Soejima, Hiroshi Kawane, Niro Okimoto, Osamu Tatara, Kazuo Takebe, Toyokazu Tamura, Kotaro Oizumi, Akira Watanabe, Kazuo Sato, Shigeo Takizawa, Kaoru Shimada, Yasuyuki Sano, Yasufumi Miyamoto, Hiroichi Tanimoto, Katsumi Komatsuzaki, Osamu Tanabe, Kazuo Ohara, Hiroyuki Kobayashi, Masataka Katsu, Akira OhishiHiroshi Hirose, Junzaburo Kabe, Hitoshi Arioka, Fumio Matsumoto, Shigeki Odagiri, Kaneo Suzuki, Masaaki Arakawa, Kouichi Wada, Nobuki Aoki, Atsuhiko Sato, Masami Taniguchi, Masatoshi Iwata, Toshihiko Takeuchi, Yoshimitsu Hayashi, Hidekazu Hanaki, Fumiyuki Kuze, Nobuaki Ikeda, Kenji Bando, Norio Inaba, Yoshiro Oda, Akira Kagioka, Takekuni Iwata, Kazukiyo Oida, Yoshiro Mochizuki, Shohei Kusaka, Tadashi Ishida, Eisaku Tanaka, Kohichi Nakatani, Fumio Miki, Eiro Tsubura, Masaru Nakagawa, Michio Yamakido, Kenji Hasegawa, Yukio Nishimoto, Shunsuke Takami, Jitsuo Yanagida, Takao Sasaki, Yukio Matsumoto, Yuji Sugimoto, Hidemi Teramoto, Takahito Hirose, Shinichi Matsuo, Atsushi Shinoda, Tsuneo Ishibashi, Masashi Takamoto, Hozumi Yamada, Osamu Katoh, Kohei Hara, Keizo Matsumoto, Atsushi Saito, Yuei Irabu, Kenji Shiroma, Mitsuyoshi Nakashima, Mitsuo Kaku, Kazuyuki Sugawara

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Sparfloxacin (SPFX), a new oral quinolone antibacterial, was evaluated for efficacy, safety and usefulness in patients with chronic respiratory tract infections by the randomized double blind comparative study using ofloxacin (OFLX) as a control drug. The patients were given either SPFX (300 mg once daily) or OFLX (200 mg three times daily) for 14 days, in principle. The results obtained were as follows : 1 ) A total of 185 patients (SPFX 97, OFLX 88) were enrolled in the trial. The number of evaluable cases according to the criteria proposed by the committee was 157 for clinical efficacy (SPFX 84, OFLX 73), 174 for side effects (SPFX 94, OFLX 80), 162 for laboratory findings (SPFX 87, OFLX 75), and 163 for usefulness (SPFX 86, OFLX 77). There was no significant difference in the rate of background factors of the patients, except in the distribution of pretreatment with antimicrobial agents, between the two groups. 2) The clinical efficacy rate judged by the committee was 82.1% (69/84) in the SPFX group and 83. 6% (61/73) in the OFLX group, and judged by the doctor in charge was 76.2% (64/84) and 79.5% (58/73), respectively, without any significant difference between the two groups. 3) The bacteriological eradication rate was 84.2% (32/38) in the SPFX group and 77.4% (24/31) in the OFLX group, without any significant difference between the two groups. 4) The incidence of side effects was 13.8% (13/94) in the SPFX group and 15.0% (12/80) in the OFLX group, and that of abnormal laboratory findings was 13.8% (12/87) in the SPFX group and 16.0% (12/75) in the OFLX group, the difference between the two groups being without any significance. 5 ) The usefulness rate judged by the committee was 70. 9% (61/86) in the SPFX group and 77.9% (60/77) in the OFLX group, and judged by the doctor in charge was 70.9% (61/86) and 72.7% (56/77), respectively, without any significant difference between the two groups. The above results indicate that SPFX (300 mg once daily) is as useful as OFLX (200 mg three times daily) in the treatment of patients with chronic respiratory tract infections.

Original languageEnglish
Pages (from-to)405-428
Number of pages24
JournalChemotherapy
Volume39
DOIs
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'Comparative study of sparfloxacin and ofloxacin in chronic respiratory tract infections by the double blind method'. Together they form a unique fingerprint.

  • Cite this

    Soejima, R., Kawane, H., Okimoto, N., Tatara, O., Takebe, K., Tamura, T., Oizumi, K., Watanabe, A., Sato, K., Takizawa, S., Shimada, K., Sano, Y., Miyamoto, Y., Tanimoto, H., Komatsuzaki, K., Tanabe, O., Ohara, K., Kobayashi, H., Katsu, M., ... Sugawara, K. (1991). Comparative study of sparfloxacin and ofloxacin in chronic respiratory tract infections by the double blind method. Chemotherapy, 39, 405-428. https://doi.org/10.11250/chemotherapy1953.39.Supplement4_405